Eur J Obstet Gynecol Reprod Biol X
Department of Obstetrics & Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Published: June 2023
Objective: diuretics have the potential to reduce intravascular volume, decrease blood pressure The aim of our study is to evaluate the effectiveness of furosemide in postpartum patients with pre-eclampsia and chronic hypertension with superimposed pre-eclampsia.
Methods: This is a retrospective cohort study. Data was extracted from the record of patients who delivered between 2017 and 2020 and had chronic hypertension or, chronic hypertension with superimposed pre-eclampsia, gestational hypertension, or pre-eclampsia. Patients who received intravenous furosemide in the postpartum period were compared to those who did not. The groups were also analyzed for fetal growth restriction, and pregnancy outcomes comparing those who did receive furosemide and those who did not.
Results: The furosemide group had a statistically significant longer postpartum length of stay (p < 0.0001), required more antihypertensive medications (p < 0.0001), medication increases (p < 0.0001), and emergent blood pressure treatment (p < 0.0001), than the group who did not. There was no difference between groups in hospital readmission, or fetal growth restriction.
Conclusion: The postpartum length of stay and rates of readmission were not decreased in the group treated with intravenous furosemide. Future prospective studies that control for pregnancy comorbidities and severity of preeclampsia are needed to determine furosemide's effect on the volume status of the postpartum pre-eclamptic patient and determine its role in the treatment of these women.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192387 | PMC |
http://dx.doi.org/10.1016/j.eurox.2023.100195 | DOI Listing |
BMJ Open
December 2024
Department of Obstetrics, University Medical Centre Utrecht, Utrecht, The Netherlands
Objective: In the puerperium, women with hypertensive disease of pregnancy remain at risk for maternal complications. The antihypertensive agent prescribed antepartum is usually continued postpartum; however, evidence regarding the most effective treatment is lacking. Therefore, we aimed to investigate which antihypertensive agent results in optimal treatment (both effectiveness and safety) of postpartum hypertension.
View Article and Find Full Text PDFAm J Perinatol
October 2024
Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.
Am J Perinatol
October 2024
Department of Obstetrics and Gynecology, Pregnancy and Perinatal Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Am J Obstet Gynecol
January 2025
Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Diego School of Medicine, UC San Diego Health, San Diego, CA.
Background: Birthing people with de novo postpartum hypertensive disorders continue to be among the populations at highest risk for severe maternal morbidity. Randomized controlled trials demonstrate a benefit of oral loop diuretics in decreasing postpartum hypertensive morbidity in patients with an antenatal diagnosis of preeclampsia. It is not known whether this same therapy benefits patients at risk for new-onset postpartum hypertension.
View Article and Find Full Text PDFCase Rep Womens Health
June 2024
Fiona Stanley Hospital, Perth, 11 robin warren drive, Murdoch, WA 6150, Australia.
This case report discusses the rare occurrence of pericarditis with preeclampsia in the antepartum through to postpartum state. A woman in her 30s presented four days postnatally with positional central chest pain, elevated blood pressure and newly deranged liver function tests. Echocardiogram demonstrated new pleural effusion and she was diagnosed with preeclampsia and superimposed pericarditis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.